FOR MORE INFORMATION PLEASE CONTACT US
In order to be able to design our website in the best possible way and to continuously improve it, we are using cookies.
By continuing to use our website, you permit the use of cookies. More information can be found in our data protection rules.
We may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds:
Atriva Therapeutics Starts Clinical Development of Novel Host-Targeting Antiviral ATR-002 Against Influenza
LightOx appoints experienced Non-Executive Directors and closes investment round
Aptamer Therapeutics and Cancer Research UK announce partnership for drug development programme
Galapagos steekt ruim €300 miljoen in zoektocht naar nieuwe medicijnen
Aanval op het bestverkochte medicijn ter wereld
De toenemende ongevoeligheid voor antibiotica is angstaanjagend
De lamme laten lopen, de blinde laten zien
Japans Itochu steekt €10 mln in Waals stamcellenbedrijf
Novartis maakt Rotterdams medicijn zes keer duurder
Aptamer Group Announces Agreement with AstraZeneca to Explore Next-Generation Drug Delivery Devices
Atriva Therapeutics announces first closing of series A financing round
Voor Big Farma zijn zeperds als Dezima part of the deal
Miljardendeal van biotechbedrijf Dezima loopt uit op flop
Xenikos partners with the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) to conduct a U.S.-based Phase 3 trial to test T-Guard(R) in acute graft-versus-host disease
Miljoenendeal van Nijmeegs biotechbedrijf met Deense Novo Nordisk
Gentherapie verdient moderne regels
Nederland loopt investeringen voor gentherapie mis
Xenikos announces data from phase I/II trial with T-Guard™ for treatment of steroid-resistant acute GVHD presented at ASH Annual Meeting
Dutch Company Xenikos Secures USD 30 Million in Series B Financing
APTAMER GROUP LTD SECURES $ 2.2 M SERIES A INVESTMENT